2-[[4-(4-methylanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol profile

ID Source	ID
PubMed CID	23648018
CHEMBL ID	236273
CHEBI ID	92619

Synonym
triazine scaffold, 27
bdbm18462
2-({4-[(4-methylphenyl)amino]-6-(pyrrolidin-1-yl)-1,3,5-triazin-2-yl}amino)ethan-1-ol
2-(4-(pyrrolidin-1-yl)-6-(p-tolylamino)-1,3,5-triazin-2-ylamino)ethanol
smr000486318
MLS001065826
CHEMBL236273
HMS2197F12
HMS3355O16
CHEBI:92619
2-[[4-(4-methylanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol
Q27164336
2-[[4-(4-methylanilino)-6-pyrrolidin-1-yl-1,3,5-triazin-2-yl]amino]ethanol

Class	Description
dialkylarylamine
tertiary amino compound	A compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
DNA polymerase eta isoform 1	Homo sapiens (human)	Potency	100.0000	0.1000	28.9256	213.3130	AID588591
geminin	Homo sapiens (human)	Potency	11.7852	0.0046	11.3741	33.4983	AID624296; AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Lysosomal acid glucosylceramidase	Homo sapiens (human)	IC50 (µMol)	10.0400	0.0300	2.3589	8.8000	AID1797734; AID301611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
mitochondrion organization	Lysosomal acid glucosylceramidase	Homo sapiens (human)
neuron projection development	Lysosomal acid glucosylceramidase	Homo sapiens (human)
glucosylceramide catabolic process	Lysosomal acid glucosylceramidase	Homo sapiens (human)
autophagy	Lysosomal acid glucosylceramidase	Homo sapiens (human)
lysosome organization	Lysosomal acid glucosylceramidase	Homo sapiens (human)
cholesterol metabolic process	Lysosomal acid glucosylceramidase	Homo sapiens (human)
determination of adult lifespan	Lysosomal acid glucosylceramidase	Homo sapiens (human)
cellular response to starvation	Lysosomal acid glucosylceramidase	Homo sapiens (human)
response to pH	Lysosomal acid glucosylceramidase	Homo sapiens (human)
microglia differentiation	Lysosomal acid glucosylceramidase	Homo sapiens (human)
regulation of macroautophagy	Lysosomal acid glucosylceramidase	Homo sapiens (human)
antigen processing and presentation	Lysosomal acid glucosylceramidase	Homo sapiens (human)
lipid storage	Lysosomal acid glucosylceramidase	Homo sapiens (human)
cerebellar Purkinje cell layer formation	Lysosomal acid glucosylceramidase	Homo sapiens (human)
pyramidal neuron differentiation	Lysosomal acid glucosylceramidase	Homo sapiens (human)
respiratory electron transport chain	Lysosomal acid glucosylceramidase	Homo sapiens (human)
termination of signal transduction	Lysosomal acid glucosylceramidase	Homo sapiens (human)
lipid glycosylation	Lysosomal acid glucosylceramidase	Homo sapiens (human)
negative regulation of protein-containing complex assembly	Lysosomal acid glucosylceramidase	Homo sapiens (human)
regulation of TOR signaling	Lysosomal acid glucosylceramidase	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	Lysosomal acid glucosylceramidase	Homo sapiens (human)
negative regulation of interleukin-6 production	Lysosomal acid glucosylceramidase	Homo sapiens (human)
T cell differentiation in thymus	Lysosomal acid glucosylceramidase	Homo sapiens (human)
response to testosterone	Lysosomal acid glucosylceramidase	Homo sapiens (human)
positive regulation of protein dephosphorylation	Lysosomal acid glucosylceramidase	Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process	Lysosomal acid glucosylceramidase	Homo sapiens (human)
positive regulation of protein-containing complex disassembly	Lysosomal acid glucosylceramidase	Homo sapiens (human)
negative regulation of MAP kinase activity	Lysosomal acid glucosylceramidase	Homo sapiens (human)
negative regulation of neuron apoptotic process	Lysosomal acid glucosylceramidase	Homo sapiens (human)
response to estrogen	Lysosomal acid glucosylceramidase	Homo sapiens (human)
sphingosine biosynthetic process	Lysosomal acid glucosylceramidase	Homo sapiens (human)
ceramide biosynthetic process	Lysosomal acid glucosylceramidase	Homo sapiens (human)
cell maturation	Lysosomal acid glucosylceramidase	Homo sapiens (human)
brain morphogenesis	Lysosomal acid glucosylceramidase	Homo sapiens (human)
homeostasis of number of cells	Lysosomal acid glucosylceramidase	Homo sapiens (human)
negative regulation of inflammatory response	Lysosomal acid glucosylceramidase	Homo sapiens (human)
neuromuscular process	Lysosomal acid glucosylceramidase	Homo sapiens (human)
neuron apoptotic process	Lysosomal acid glucosylceramidase	Homo sapiens (human)
establishment of skin barrier	Lysosomal acid glucosylceramidase	Homo sapiens (human)
microglial cell proliferation	Lysosomal acid glucosylceramidase	Homo sapiens (human)
motor behavior	Lysosomal acid glucosylceramidase	Homo sapiens (human)
cellular response to tumor necrosis factor	Lysosomal acid glucosylceramidase	Homo sapiens (human)
hematopoietic stem cell proliferation	Lysosomal acid glucosylceramidase	Homo sapiens (human)
response to dexamethasone	Lysosomal acid glucosylceramidase	Homo sapiens (human)
lymphocyte migration	Lysosomal acid glucosylceramidase	Homo sapiens (human)
response to thyroid hormone	Lysosomal acid glucosylceramidase	Homo sapiens (human)
beta-glucoside catabolic process	Lysosomal acid glucosylceramidase	Homo sapiens (human)
positive regulation of protein lipidation	Lysosomal acid glucosylceramidase	Homo sapiens (human)
positive regulation of neuronal action potential	Lysosomal acid glucosylceramidase	Homo sapiens (human)
positive regulation of autophagy of mitochondrion in response to mitochondrial depolarization	Lysosomal acid glucosylceramidase	Homo sapiens (human)
autophagosome organization	Lysosomal acid glucosylceramidase	Homo sapiens (human)
regulation of lysosomal protein catabolic process	Lysosomal acid glucosylceramidase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
galactosylceramidase activity	Lysosomal acid glucosylceramidase	Homo sapiens (human)
glucosylceramidase activity	Lysosomal acid glucosylceramidase	Homo sapiens (human)
signaling receptor binding	Lysosomal acid glucosylceramidase	Homo sapiens (human)
scavenger receptor binding	Lysosomal acid glucosylceramidase	Homo sapiens (human)
protein binding	Lysosomal acid glucosylceramidase	Homo sapiens (human)
glucosyltransferase activity	Lysosomal acid glucosylceramidase	Homo sapiens (human)
steryl-beta-glucosidase activity	Lysosomal acid glucosylceramidase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
lysosome	Lysosomal acid glucosylceramidase	Homo sapiens (human)
lysosomal membrane	Lysosomal acid glucosylceramidase	Homo sapiens (human)
endoplasmic reticulum	Lysosomal acid glucosylceramidase	Homo sapiens (human)
Golgi apparatus	Lysosomal acid glucosylceramidase	Homo sapiens (human)
trans-Golgi network	Lysosomal acid glucosylceramidase	Homo sapiens (human)
lysosomal lumen	Lysosomal acid glucosylceramidase	Homo sapiens (human)
extracellular exosome	Lysosomal acid glucosylceramidase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay ID	Title	Year	Journal	Article
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID301611	Inhibition of glucocerebrosidase	2007	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21	N4-phenyl modifications of N2-(2-hydroxyl)ethyl-6-(pyrrolidin-1-yl)-1,3,5-triazine-2,4-diamines enhance glucocerebrosidase inhibition by small molecules with potential as chemical chaperones for Gaucher disease.
AID1797734	GC Enzyme Assay from Article 10.1016/j.bmcl.2007.08.050: \\N(4)-Phenyl modifications of N(2)-(2-hydroxyl)ethyl-6-(pyrrolidin-1-yl)-1,3,5-triazine-2,4-diamines enhance glucocerebrosidase inhibition by small molecules with potential as chemical chaperones fo	2007	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21	N4-phenyl modifications of N2-(2-hydroxyl)ethyl-6-(pyrrolidin-1-yl)-1,3,5-triazine-2,4-diamines enhance glucocerebrosidase inhibition by small molecules with potential as chemical chaperones for Gaucher disease.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (40.00)	29.6817
2010's	2 (40.00)	24.3611
2020's	1 (20.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes
2-[[4-(4-chloroanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol [no description available]	2.03	1	dialkylarylamine; tertiary amino compound
2-[[4-(3-methylanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol [no description available]	2.03	1	dialkylarylamine; tertiary amino compound
2-[[4-[2-[(2-methylpropan-2-yl)oxy]anilino]-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol [no description available]	2.03	1	aromatic ether
2-[[4-(5-chloro-2-methoxyanilino)-6-(1-piperidinyl)-1,3,5-triazin-2-yl]amino]ethanol [no description available]	2.03	1	methoxybenzenes; substituted aniline
2-[[4-(2-chloroanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol [no description available]	2.03	1	dialkylarylamine; tertiary amino compound
2-[[4-(2-methoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol [no description available]	2.03	1	methoxybenzenes; substituted aniline
2-[[4-(3-methoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol [no description available]	2.03	1	methoxybenzenes; substituted aniline
2-[[4-(4-methoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol [no description available]	2.03	1	methoxybenzenes; substituted aniline
2-[[4-(2-hydroxyethylamino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]phenol [no description available]	2.03	1	dialkylarylamine; tertiary amino compound
2-[[4-(2-phenoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol [no description available]	2.03	1	aromatic ether
2-[[4-(1-pyrrolidinyl)-6-[2-(trifluoromethoxy)anilino]-1,3,5-triazin-2-yl]amino]ethanol [no description available]	2.03	1	aromatic ether
2-[[4-(5-chloro-2-ethoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol [no description available]	2.03	1	aromatic ether
2-[[4-(5-chloro-2-propan-2-yloxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol [no description available]	2.03	1	aromatic ether
2-[[4-(2-hydroxyethylamino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]benzamide [no description available]	2.03	1	benzamides
4-[[4-(2-methoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]-1-butanol [no description available]	2.03	1	methoxybenzenes; substituted aniline
N-[2-[[4-(2-hydroxyethylamino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]phenyl]acetamide [no description available]	2.03	1	acetamides; anilide

Condition	Relationship Strength	Studies
Acid beta-Glucosidase Deficiency [description not available]	2.03	1
Gaucher Disease An autosomal recessive disorder caused by a deficiency of acid beta-glucosidase (GLUCOSYLCERAMIDASE) leading to intralysosomal accumulation of glycosylceramide mainly in cells of the MONONUCLEAR PHAGOCYTE SYSTEM. The characteristic Gaucher cells, glycosphingolipid-filled HISTIOCYTES, displace normal cells in BONE MARROW and visceral organs causing skeletal deterioration, hepatosplenomegaly, and organ dysfunction. There are several subtypes based on the presence and severity of neurological involvement.	2.03	1
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1

2-[[4-(4-methylanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol

Cross-References

Synonyms (13)

Drug Classes (2)

Protein Targets (3)

Potency Measurements

Inhibition Measurements

Biological Processes (52)

Molecular Functions (7)

Ceullar Components (7)

Bioassays (13)

Research

Studies (5)

Market Indicators

Research Demand Index: 12.56

Study Types

2-[[4-(4-methylanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol

Cross-References

Synonyms (13)

Drug Classes (2)

Protein Targets (3)

Potency Measurements

Inhibition Measurements

Biological Processes (52)

Molecular Functions (7)

Ceullar Components (7)

Bioassays (13)

Research

Studies (5)

Market Indicators

Research Demand Index: 12.56

Study Types

Related Drugs (16)

Related Conditions (4)